No abstract available.
Aged, 80 and over ; Biopsy ; Carcinoma, Papillary/chemistry/*secondary ; Female ; Humans ; Immunohistochemistry ; Liver Neoplasms/chemistry/*secondary ; Pancreatic Neoplasms/chemistry/*pathology ; Tumor Markers, Biological/analysis

Tumor-to-tumor metastasis is rare. We report a case of metastatic renal cell carcinoma in meningioma. A 67-year-old woman presented a two-week history of motor dysphagia and decreased short-term memory. She had undergone a left radical nephrectomy for a renal cell carcinoma 7 years ago, and had not received any adjuvant therapy. MRI disclosed a 3.0 x 3.0 x 3.0-cm sized round tentorial-based extraaxial mass with peritumoral edema in the left posterior temporal lobe. During operation, the tumor was found to be an encapsulated mass firmly attached to the tentorium. Histologically, the tumor was a meningotheliomatous meningioma extensively infiltrated by metastatic renal cell carcinoma, accompanying widespread coagulative necrosis. Immunohistochemical staining for cytokeratin revealed strong positivity only in the renal cell carcinoma component. The patient's postoperative course was uneventful. Post-operative radiation therapy was applied to the whole brain. Three months after operation, the patient developed right hemiparesis and dysphagia. Brain MRI at that time did not reveal recurrence or any other causative lesions, although the whole body scan disclosed uptake at the second lumbar vertebra and rib. The patient refused further treatment.
Aged ; Carcinoma, Renal Cell/secondary* ; Carcinoma, Renal Cell/chemistry ; Case Report ; Female ; Human ; Keratin/analysis ; Kidney Neoplasms/secondary* ; Kidney Neoplasms/chemistry ; Magnetic Resonance Imaging ; Meningeal Neoplasms/pathology* ; Meningioma/pathology*

The identification of primary location of a metastatic tumor is a difficult diagnostic problem and sometimes can be facilitated by the use of immunohistochemical markers. Thyroid transcription factor-1 (TTF-1) is a 38-kDa nuclear homeodomain transcription factor that is expressed specifically in lung or thyroid neoplasms. Cytokeratin 20 (CK20) is a 46-kDa low-molecular-weight cytokeratin that shows restricted expression in adenocarcinomas of the gastrointestinal tract (GIT) and transitional cell carcinomas of the urinary tract. We studied the immunohistochemical expression of TTF-1 and CK20 in 68 metastatic carcinomas in cervical lymph nodes. The primary sites were the lung in 29 cases, stomach in 13, colorectum in 3, and other sites in 23. TTF-1 expression was detected in 69.0% of metastatic lung carcinomas and none in metastatic GIT carcinomas, whereas CK20 expression was detected in 68.8% of metastatic GIT carcinomas and none of metastatic lung carcinomas. TTF-1 had a specificity of 0.95 and a sensitivity of 0.69 for metastatic lung carcinoma, whereas CK20 had a specificity of 1.00 and a sensitivity of 0.69 for metastatic GIT carcinoma. These results indicate that TTF-1 and CK20 should be the first choice as a component of antibody panel to prove or to exclude the lung and GIT origin, respectively, especially in patients presenting with metastatic carcinomas of unknown primary site.
Adenocarcinoma/chemistry/pathology/secondary ; Carcinoma/chemistry/pathology/*secondary ; Gastrointestinal Neoplasms/chemistry/pathology ; Homeodomain Proteins/analysis ; Humans ; Intermediate Filament Proteins/*analysis/immunology ; Keratin-20 ; Lung Neoplasms/chemistry/pathology ; Lymph Nodes/chemistry/pathology ; Lymphatic Metastasis/*diagnosis/pathology ; Neck ; Neoplasms, Unknown Primary/chemistry/pathology ; Nuclear Proteins/*analysis/immunology ; Sensitivity and Specificity ; Transcription Factors/*analysis/immunology ; Tumor Markers, Biological/analysis

No abstract available.
Adenocarcinoma/chemistry/*drug therapy/secondary ; Adult ; Antineoplastic Agents/*therapeutic use ; Biopsy ; Carcinoma, Large Cell/chemistry/*pathology ; Carcinoma, Neuroendocrine/chemistry/*pathology ; Carcinoma, Non-Small-Cell Lung/chemistry/*drug therapy/secondary ; *Drug Resistance, Neoplasm ; Humans ; Lung Neoplasms/chemistry/*drug therapy/pathology ; Magnetic Resonance Imaging ; Male ; Protein Kinase Inhibitors/*therapeutic use ; Quinazolines/*therapeutic use ; Tomography, X-Ray Computed ; Treatment Outcome ; Tumor Markers, Biological/analysis

Cutaneous metastases originating from an internal cancer are relatively uncommon in clinical practice, and metastatic lesions to the breast are rarer than those to the skin. Skin metastases of lung cancer, which may be the first sign of the disease, usually indicate progressive disease and a poor prognosis. We describe a 47-year-old male who presented with recurring masses in the lumbar region bilaterally and the right breast. Immunohistochemical findings and radiological imaging suggested lung cancer. This is the first reported case of small cell lung cancer metastasizing to two separate, uncommon sites, the skin and breast.
Biopsy ; Breast Neoplasms, Male/chemistry/*secondary/therapy ; Fatal Outcome ; Humans ; Immunohistochemistry ; Lung Neoplasms/chemistry/*pathology/therapy ; Male ; Middle Aged ; Skin Neoplasms/chemistry/*secondary/therapy ; Small Cell Lung Carcinoma/chemistry/*secondary/therapy ; Tomography, X-Ray Computed ; Treatment Outcome ; Tumor Markers, Biological/analysis

OBJECTIVEThe purpose of this study was to screen sialyl Lewis(a) (sLe(a)) in the tumors of patients with oral squamous cell carcinoma (OSCC) and to explore the association of sialyl Lewis(a) expression with local lymph node metastasis.

METHODSSpecimen from 38 patients with primary OSCC were obtained and analyzed by immunohistochemical methods.

RESULTSThe expression of sLe(a) protein, but not E-selectin, of OSCCs significantly correlated to the local lymph node metastasis. sLe(a) was expressed in 79% (15/19) of the metastatic cases compared with 21% (4/19) of the non-metastasis ones, indicated the association of sLe(a) expression with the local lymph involvement.

CONCLUSIONHigh expression of sLe(a) in OSCC may be related to the metastasis of cervical lymph nodes and it seems useful in predicting poor prognosis in OSCC.

Adult ; Aged ; Antigens, Tumor-Associated, Carbohydrate ; analysis ; Biomarkers, Tumor ; analysis ; Carcinoma, Squamous Cell ; chemistry ; genetics ; pathology ; secondary ; E-Selectin ; analysis ; genetics ; Female ; Gangliosides ; analysis ; genetics ; Humans ; Immunohistochemistry ; Lymphatic Metastasis ; Male ; Middle Aged ; Mouth Neoplasms ; chemistry ; genetics ; pathology

Age Factors ; Bone Neoplasms ; secondary ; Breast Neoplasms ; chemistry ; genetics ; pathology ; Carcinoma, Ductal, Breast ; chemistry ; genetics ; pathology ; Carcinoma, Intraductal, Noninfiltrating ; chemistry ; genetics ; pathology ; Female ; Gene Expression Profiling ; Humans ; Ki-67 Antigen ; analysis ; Lymphatic Metastasis ; Prognosis ; Receptor, ErbB-2 ; analysis ; Receptors, Estrogen ; analysis ; Receptors, Progesterone ; analysis ; Tumor Burden

OBJECTIVETo prepare anticancer nanoparticles for targeting therapy for oral cancer lymph node metastasis.

METHODSThe activated carbon nanoparticles (CH-NP) were prepared for drug carrier. Pingyangmycin (PYM), a high sensitive anticancer drug for oral squamous cell carcinoma, were selected as model drug. The activated carbon nanoparticles and PYM were mixed with saline and shaken 20 minutes so that PYM was absorbed on activated carbon enough, resulting in a new formulation of PYM (PYM-CH-NP). The absorbency of PYM on activated carbon nanoparticles was evaluated.

RESULTSThe diameter distribution for CH-NP ranged form 136 nm, to 540 nm, the average diameter was 176 nm. The proportion of CH-NP to PYM was increased and more absorbency of PYM on activated carbon nanoparticles was achieved.

CONCLUSIONThe activated carbon nanoparticles has high absorbency of PYM. The new formulation PYM-CH-NP can be used as targeting therapy of cervical lymph node metastasis by peri-cancer submucosal injection.

Antibiotics, Antineoplastic ; administration & dosage ; pharmacokinetics ; Bleomycin ; administration & dosage ; analogs & derivatives ; pharmacokinetics ; Carbon ; chemistry ; Carcinoma, Squamous Cell ; drug therapy ; secondary ; Humans ; Injections, Intralymphatic ; Lymph Nodes ; drug effects ; pathology ; Lymphatic Metastasis ; Mouth Neoplasms ; drug therapy ; pathology ; Nanoparticles ; Neck

OBJECTIVETo investigate the practicability of detecting the micrometastases in lymph nodes of no-small-cell lung cancer (NSCLC) by means of the immunohistochemical (IHC) staining.

METHODSThe lymph node samples were taken from the patients with NSCLC during the operations. Firstly, each resulting tissue block was processed for routine paraffin embedding. Then the 6 approximately 10 serial sections were chosen, each 5 microm thick, from every paraffin block of the lymph node. Finally, the first and the second last sections of each lymph node were stained by hematoxylin eosin (HE), and the other serial sections were used for the IHC staining examination with the monoclonal antibody against cytokeratin 19.

RESULTSThe paraffin embedded sections of 195 regional lymph nodes from 25 patients with NSCLC were examined by HE staining. Thirty lymph nodes in 9 patients revealed gross nodal metastases, and none of lymph node in 25 patients showed micrometastatic tumor cells. Frozen tissue sections from 135 regional lymph nodes that were staged as free of metastases by HE staining were screened by IHC staining. Thirty-one lymph nodes in 9 patients showed micrometastatic tumor cells. Five of sixteen patients staged as PN(0) had hilum lymph nodal micrometastases, versus four of nine patients with stage PN(1) had mediastinal lymph nodal micrometastases. There was a significant difference between two groups (chi(2)=52.900, P=0.0193).

CONCLUSIONSConventional HE staining can accurately detect gross nodal metastases in the lymph nodes of patients with NSCLC, but is unfit for detecting lymph nodal micrometastases. IHC staining analysis can significantly facilitate the detection of occult micrometastatic tumor cells in lymph nodes of NSCLC, and its assessment of nodal micrometastases can provide a refinement of TNM stage for partial patients with stage I to II NSCLC.

Aged ; Carcinoma, Non-Small-Cell Lung ; diagnosis ; metabolism ; secondary ; Female ; Humans ; Immunohistochemistry ; Keratin-19 ; analysis ; Lung Neoplasms ; metabolism ; pathology ; Lymph Nodes ; chemistry ; pathology ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging

No abstract available.
Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/*analysis ; Biopsy ; Carcinoma, Ductal, Breast/*chemistry/*secondary/therapy ; Chemotherapy, Adjuvant ; Disease Progression ; Female ; Humans ; Immunohistochemistry ; Lymph Node Excision ; Lymphatic Metastasis ; Magnetic Resonance Imaging ; Mastectomy ; Neoadjuvant Therapy ; Neoplasm Staging ; Receptors, Estrogen/*analysis ; Skin Neoplasms/*chemistry/*secondary ; Time Factors ; Treatment Outcome ; Triple Negative Breast Neoplasms/*chemistry/*pathology/therapy